A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration ...

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price ...

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who ...

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings. Patients with inflammatory bowel disease (IBD) who transitioned from ...

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

Number 5: A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.